切换至 "中华医学电子期刊资源库"

中华口腔医学研究杂志(电子版) ›› 2013, Vol. 07 ›› Issue (01) : 15 -21. doi: 10.3877/cma.j.issn.1674-1366.2013.01.004

基础研究

尼妥珠单抗联合顺铂对人舌鳞状细胞癌细胞株CAL-27 的抑制作用
王秀力1, 孟箭2,()   
  1. 1. 221009 徐州市中心医院中心实验室
    2. 221009 徐州市中心医院口腔科
  • 收稿日期:2012-06-18 出版日期:2013-02-01
  • 通信作者: 孟箭
  • 基金资助:
    徐州市科技发展项目(XZZD1017)

Inhibitory effects of nimotuzumab combined with DDP on human tongue squamous carcinoma cell line CAL-27

Xiu-li WANG1, Jian MENG1,()   

  1. 1. Xuzhou Central Hospital,Xuzhou 221009,China
  • Received:2012-06-18 Published:2013-02-01
  • Corresponding author: Jian MENG
引用本文:

王秀力, 孟箭. 尼妥珠单抗联合顺铂对人舌鳞状细胞癌细胞株CAL-27 的抑制作用[J/OL]. 中华口腔医学研究杂志(电子版), 2013, 07(01): 15-21.

Xiu-li WANG, Jian MENG. Inhibitory effects of nimotuzumab combined with DDP on human tongue squamous carcinoma cell line CAL-27[J/OL]. Chinese Journal of Stomatological Research(Electronic Edition), 2013, 07(01): 15-21.

目的

研究尼妥珠单抗(h-R3)联合顺铂(DDP)对人舌鳞状细胞癌(以下简称舌鳞癌)细胞株CAL-27 的生长抑制作用。

方法

常规培养CAL-27 细胞,以5 × 104/ml 的细胞密度种植细胞,实验分为对照组、h-R3 组、DDP 组及h-R3 联合DDP 用药组共4 组。 CCK-8 法检测h-R3 及h-R3 联合DDP 组在不同时间对CAL-27 细胞的生长抑制情况;分别于24、48 及72 h 对各组进行摄片并收集细胞培养上清,酶联免疫吸附法(ELISA)检测h-R3 组及h-R3 联合DDP 组在不同时间对CAL-27 细胞分泌表皮生长因子(EGF)及血管内皮细胞生长因子(VEGF)含量的影响,同时采用细胞凋亡-Hoechst 染色试剂盒检测CAL-27 加入不同药物后的凋亡情况。

结果

h-R3 和DDP 单药对CAL-27 细胞生长均有抑制作用且呈时间和剂量依赖性,两药单独作用72 h 后,对CAL-27 细胞的最大抑制率分别为(26.91 ±7.08)%和(89.18±4.73)%。 两药联用对CAL-27 细胞增殖的最大抑制率为(93.26±1.03)%,联合用药可提高细胞增殖抑制率,呈相加作用;h-R3 及h-R3 联合DDP 组不同时间凋亡率与对照组比较差异有统计学意义(P<0.01),随着作用时间增加细胞凋亡率亦呈升高趋势;h-R3 及h-R3 联合DDP 组不同时间CAL-27 细胞分泌EGF 与VEGF 含量与对照组比较均显著降低(P<0.01),而且联合用药与单药比较,EGF 和VEGF 含量也显著降低(P<0.05)。

结论

h-R3 在体外与DDP 联用可以提高对CAL-27 细胞增殖抑制及凋亡作用,同时对CAL-27 细胞分泌EGF 与VEGF 具有抑制作用。

Objective

To study the inhibitory effects of nimotuzumab combined with DDP on human tongue squamous carcinoma Cell Line CAL-27.

Methods

CAL-27 cells were cultured by the density of 5 × 104/ml. H-R3 group,DDP group,h-R3+DDP group and control group containing 10%FBS were used to study the inhibitory effects of h-R3 combined with DDP on CAL-27 cells. CCK-8 assay was performed to evaluated the growth inhibitory ratio of CAL-27 cells in the different time. After CAL-27 cells were cultured for 24,48 and 72 h,the supernatant liquid of which were collected and used for enzyme-linked immunosorbent assay (ELISA) to detect the content of EGF and VEGF. Different drug alone or combination effect on CAL-27 cells apoptosis changes were determined by Hoechst Staining Kit.

Results

H-R3 and DDP both inhibited the growth of CAL-27 cells in a time and dosedependent manner. The single drug of h-R3 or DDP had effect on CAL-27 cells,after 72 hour treatment,the proliferation inhibition ratio of CAL-27 cells was (26.91±7.08)% and (89.18±4.73)%seperately. Combination of h-R3 and DDP could increase the proliferation inhibition ratio of CAL-27 cells,which was (93.26 ± 1.03)% after 72 hour treatment,and the two drugs had synergistic role on the proliferation inhibition. After the drug h-R3 and DDP alone or combined treatment,the apoptosis ratio of combination group was increased,and the apoptosis ratio was increased when treatment time prolonged.The content of EGF and VEGF in h-R3 and DDP group were obviously degraded than that in control group (P<0.01),and the content of EGF and VEGF in h-R3+DDP group were obviously degraded than that in h-R3 or DDP group (P<0.05).

Conclusion

H-R3,DDP and h-R3 combined with DDP could significantly inhibit cell line CAL-27 proliferation and the secretion of EGF and VEGF,also could induce cell apoptosis,and the effect was in accordance with concentration and time-dependent.

图1 50 μg/ml 的h-R3 与1.0 μg/ml 的DDP 及二者联合用药24、48 和72 h 后与对照组比较的细胞生长状态(×200)
图2 h-R3 对CAL-27 细胞生长抑制的量效、时效曲线
表1 h-R3 不同浓度及时间对CAL-27 细胞生长的抑制率(±s,%)
图3 DDP 对CAL-27 细胞生长抑制的量效、时效曲线
表2 DDP 不同浓度及时间对CAL-27 细胞生长的抑制率(±s,%)
图4 h-R3 与DDP 两药联用对CAL-27 细胞生长抑制的量效、时效曲线
表3 不同浓度h-R3 及DDP 联合用药在不同时间对CAL-27细胞生长的抑制率(±s,%)
图5 h-R3 与DDP 两药联用24 h 后CAL-27 细胞凋亡情况(×400) A:正常CAL-27 细胞;B:联合用药24 后的CAL-27 细胞(箭头指示为凋亡细胞)
表4 h-R3 与DDP 两药联用时CAL-27 细胞的凋亡情况(±s,%)
图6 单独使用不同浓度的h-R3 及联合不同浓度的DDP 作用于CAL-27 细胞24、48 及72 h 后EGF 含量的比较 h-R3 的终浓度分别为5、10、20、50、100 及200 μg/ml,DDP 终浓度分别为0.125、0.25、0.5、1.0、2.0 及5.0 μg/ml
图7 单独使用不同浓度的h-R3 及联合不同浓度的DDP 作用于CAL-27 细胞24、48 及72 h 后VEGF 含量的比较 h-R3 的终浓度分别为5、10、20、50、100 及200 μg/ml,DDP 终浓度分别为:0.125、0.25、0.5、1.0、2.0 及5.0 μg/ml
1
Bello IO,Soini Y,Salo T. Prognostic evaluation of oral tongue cancer: means,markers and perspectives (Ⅰ). Oral Oncol,2010,46(9):630-635.
2
Bello IO,Soini Y,Salo T. Prognostic evaluation of oral tongue cancer: means,markers and perspectives (Ⅱ). Oral Oncol,2010,46(9):636-643.
3
Lee SJ,Choi JY,Lee HJ,et al. Prognostic Value of Volume-Based (18)F-Fluorodeoxyglucose PET/CT Parameters in Patients with Clinically Node-Negative Oral Tongue Squamous Cell Carcinoma. Korean J Radiol,2012,13(6):752-759.
4
郭伟. 晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析. 口腔颌面外科杂志,2012,22(2):77-81.
5
Laskin JJ,Sandler AB. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev,2004,30(1):1-17.
6
Lage A,Crombet T,González G. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Ann Med,2003,35(5):327-336.
7
Hong J,Peng Y,Liao Y,et al. Nimotuzumab prolongs survival in patients with malignant gliomas: A phase Ⅰ/Ⅱclinical study of concomitant radiochemotherapy with or without nimotuzumab.Exp Ther Med,2012,4(1):151-157.
8
Rodríguez MO,Rivero TC,del Castillo Bahi R,et al.Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther,2010,9(5):343-349.
9
Jemal A,Siegel R,Xu J,et al. Cancer statistics,2010. CA Cancer J Clin,2010,60(5):277-300.
10
Agulnik M. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol,2012,29(4):2481-2491.
11
Fung C,Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs,2010,15(3):355-373.
12
Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer,2005,103 (12):2435-2446.
13
Ang KK,Berkey BA,Tu X,et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res,2002,62(24):7350-7356.
14
Temam S,Kawaguchi H,El-Naggar AK,et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol,2007,25(16):2164-2170.
15
凌华毓,顾康生. 尼妥珠单抗联合表阿霉素对人肝癌细胞株HepG2 体外生长的影响. 临床肿瘤学杂志,2011,16(2):113-118.
16
Ling Y,Chen J,Tao M,et al. A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma. J Thorac Dis,2012,4(1):58-62.
[1] 周圆圆, 周怡, 段亚阳, 张怡卿, 朱峰宇, 张超学. 低强度超声缓解顺铂所致小鼠卵巢损伤的实验研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(12): 1132-1141.
[2] 赵向阳, 刘双池, 张懿刚, 陶滔, 谈燚. 顺铂对肝细胞癌Hep3B细胞程序性死亡配体1表达及药物敏感性的研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(01): 51-55.
[3] 李龙, 丁霏霏, 赵斌, 程志斌. 替吉奥联合奥沙利铂对比替吉奥联合顺铂治疗晚期胃癌的Meta分析[J/OL]. 中华普通外科学文献(电子版), 2022, 16(05): 382-388.
[4] 邵浩仁, 郭佳. 铁死亡的分子机制及其在前列腺癌治疗中的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(03): 294-298.
[5] 吕嘉文, 陈昕昕, 陆婉君, 吴冠楠, 顾晓凌, 吕镗烽, 王栋, 宋勇. 基于功能化新型金属有机框架的化学-光动力联合治疗逆转肺癌细胞顺铂耐药的体外分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(06): 847-854.
[6] 刘康, 洪礼虎, 刘根, 彭力, 李祥攀. 复方红豆杉胶囊联合GP化疗对晚期NSCLC疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(02): 284-287.
[7] 孟俊杰, 李晓辉, 武晋荣, 郭光伟. 卡瑞丽珠单抗联合TP方案对晚期肺癌患者的疗效及作用机制分析[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(05): 724-726.
[8] 崔鹤清, 洪梅, 刘志远, 朱诺. SBRT同步贝伐珠单抗联合TP化疗对局部晚期NSCLC疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2021, 14(05): 596-598.
[9] 许锐, 钱勇, 张海燕. miR-515-5p靶向RING1增强NSCLC A549/DDP细胞顺铂敏感性分析[J/OL]. 中华肺部疾病杂志(电子版), 2021, 14(05): 559-563.
[10] 吴亚萍, 吴颖. miR-340-5p调控PDE4D表达对胃癌细胞顺铂耐药性的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2023, 13(06): 346-354.
[11] 王甜甜, 温媛, 李振, 叶美红, 郭影, 马双. 和厚朴酚调控Nrf2/ARE通路对胃癌细胞的顺铂化疗敏感性的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2023, 13(04): 202-209.
[12] 袁晓利, 李杨, 邓微, 聂世娟. PDZ连接激酶诱导自噬对肺癌细胞顺铂化疗敏感性的影响研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2021, 11(04): 222-230.
[13] 曹文玺, 陈箫, 竺来法, 周永平. 尼妥珠单抗联合白蛋白结合型紫杉醇治疗胰腺癌的有效性及安全性分析[J/OL]. 中华临床医师杂志(电子版), 2023, 17(04): 409-413.
[14] 江丹贤, 曹金鑫, 杨柳, 黄静. 诱导阶段加/不加尼妥珠单抗序贯同步放化疗联合尼妥珠单抗治疗局部晚期鼻咽癌的单中心分析[J/OL]. 中华临床医师杂志(电子版), 2022, 16(12): 1248-1255.
[15] 丁洁, 刘兴祥, 申小章, 王彩霞, 郭卿. 纳米蛋白结合型紫杉醇联合顺铂治疗食管鳞状细胞癌的疗效分析[J/OL]. 中华临床医师杂志(电子版), 2022, 16(09): 892-896.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?